Loading...
Market
Will NHS England approve Kisunla™ for Alzheimer's by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
NHS England's official announcements or website
Story
Eli Lilly's Second 'Game-Changing' Alzheimer's Drug Kisunla™ Approved in UK
Oct 23, 2024, 09:30 AM
Eli Lilly's Alzheimer's treatment, Kisunla™ (donanemab-azbt), has received marketing authorization in Great Britain. The approval by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) allows the drug to be used for treating mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients who are Apolipoprotein E Ε4 heterozygotes or non-carriers. This marks a significant development in Alzheimer's treatment options available in the UK. The drug, which trades under the ticker $LLY, is considered the second 'game-changing' Alzheimer's drug to receive approval in the UK.
View original story
Similar markets
Yes • 50%
No • 50%
Lecanemab • 25%
Aducanumab • 25%
Another new drug • 25%
No approval • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
